Kallikrein-2 inhibitor, (KLK2a) -5mg

Overview

The Kallikrein-2 inhibitor, KLK2a, is a critical research tool for scientists studying prostate cancer and glandular kallikrein enzymes. This 9 amino acid linear peptide specifically inhibits human glandular kallikrein enzyme, kallikrein-2 (KLK2), which is often elevated in tumor tissues and serum of prostate cancer patients. By inhibiting KLK2, researchers can explore promising therapeutic approaches to target this cancer and contribute to advancing prostate cancer treatment.

Key Features

• Inhibits kallikrein-2, a key biomarker for prostate cancer.
• 9 amino acid linear peptide designed for specific interaction with KLK2.
• Promotes research in cancer treatment and diagnostics.
• Available in a convenient 5 mg format for ease of use.

Specifications

FAQ

What is KLK2 and why is it important?

KLK2, or human glandular kallikrein-2, is a serine protease that is associated with prostate cancer. Elevated levels of KLK2 can be indicative of disease presence, making it a valuable biomarker for diagnostics and research in cancer therapy.

How is KLK2a used in research?

KLK2a is primarily used as an inhibitor in experimental studies to understand the role of KLK2 in prostate cancer. By suppressing KLK2 activity, researchers can investigate potential pathways for therapeutic intervention and gain insights into cancer biology.

Where can I find related peptides?

For a comprehensive selection of related peptides, check out our Peptides catalogwhich includes various inhibitors and substrates tailored for your research needs.

Enhance your research capabilities with KLK2a. Shop now to get your Kallikrein-2 inhibitor and explore further studies in prostate cancer.

Related Products

• PKG Substrate [RKRSRAE], Glasstide
• Autocamtide-2 [KKALRRQETVDAL]
• CREBtide [KRREILSRRPSYR], 5-FAM labeled